Duopharma Biotech Berhad Balance Sheet Health
Financial Health criteria checks 4/6
Duopharma Biotech Berhad has a total shareholder equity of MYR696.0M and total debt of MYR524.5M, which brings its debt-to-equity ratio to 75.4%. Its total assets and total liabilities are MYR1.4B and MYR656.9M respectively. Duopharma Biotech Berhad's EBIT is MYR89.8M making its interest coverage ratio 4.6. It has cash and short-term investments of MYR260.4M.
Key information
75.4%
Debt to equity ratio
RM 524.50m
Debt
| Interest coverage ratio | 4.6x |
| Cash | RM 260.42m |
| Equity | RM 696.05m |
| Total liabilities | RM 656.88m |
| Total assets | RM 1.35b |
Recent financial health updates
These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively
Oct 21
Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly
May 22Duopharma Biotech Berhad (KLSE:DPHARMA) Seems To Use Debt Quite Sensibly
Feb 12Recent updates
Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005
Aug 27Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018
Apr 04Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price
Feb 17These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively
Oct 21Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005
Aug 18Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)
Aug 07Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year
Mar 28Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)
Mar 27We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings
Nov 26Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021
Nov 25Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005
Aug 20Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly
May 22Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend
Apr 13A Look At The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)
Mar 14Duopharma Biotech Berhad (KLSE:DPHARMA) Seems To Use Debt Quite Sensibly
Feb 12Do Institutions Own Duopharma Biotech Berhad (KLSE:DPHARMA) Shares?
Jan 28
Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?
Jan 12Financial Position Analysis
Short Term Liabilities: DPHARMA's short term assets (MYR725.3M) exceed its short term liabilities (MYR167.6M).
Long Term Liabilities: DPHARMA's short term assets (MYR725.3M) exceed its long term liabilities (MYR489.3M).
Debt to Equity History and Analysis
Debt Level: DPHARMA's net debt to equity ratio (37.9%) is considered satisfactory.
Reducing Debt: DPHARMA's debt to equity ratio has increased from 52% to 75.4% over the past 5 years.
Debt Coverage: DPHARMA's debt is not well covered by operating cash flow (17.9%).
Interest Coverage: DPHARMA's interest payments on its debt are well covered by EBIT (4.6x coverage).